Dependerá de las cláusulas, pero si se aprueba y se entrega en tiempo no creo. Al menos las cantidades comprometidas en firme. Además, creo que los contratos contemplan las variantes en caso de necesitarse.
Sobre los resultados de Moderna de la gripe, que por cierto cae ahora incluso menos que Novavax, red los resume perfectamente:
The results are not bad as they are non inferior from a stats perspective, but not really. They speculate they can go lower in dose to reduce reactions, a clue that there are indeed AEs and they are likely as bad as seen with CoViD. But it’s also a clue that at 50ug they can’t compete on costs with Fluzone or Fluzone HD. And since Fluzone is not as good as NVAX NF they can’t compete on costs or on immunogenic responses.
All in all it’s not bad, but it’s also absolutely not good either.